Pericyte

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Retrieved on: 
Monday, April 22, 2024
Brain, Euronext Growth, Pericyte, IDUA, Traffic barrier, Integrin alpha M, HSPC, Mouse, CD4, Myelocyte, CD20, Cell, Intron, DNA, Therapy, Patient, Gene, Society, BBB, DSM-IV codes, Mucopolysaccharidosis, Vaccine

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first data exploring novel TALEN® editing processes in hematopoietic stem and progenitor cells (HSPCs) at the American Society of Gene and Cell Therapy (ASGCT) being held on May 7-11, 2024.

Key Points: 
  • “These two posters showcase the potential and versatility of the TALEN® technology to promote efficient gene insertion in HSPCs.
  • Cellectis has developed a TALEN® mediated promoter-less intron editing technology that enables the expression of a therapeutic transgene exclusively by monocyte derived from edited HSPCs.
  • This novel editing approach is an important addition to the HSPC gene editing toolbox that might unlock new strategies for the treatment of metabolic and neurological diseases.
  • Cellectis has developed and optimized a novel gene editing process, leveraging the TALEN® technology and circular single strand DNA template delivery, enabling highly efficient gene insertion in HSPCs.

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical trial, PDT, Macrophage, Downregulation and upregulation, Ovarian cancer, BRCA, ECM, Pericyte, Apoptosis, Nanoparticle, Cervical cancer, GBM, Patient, Neoplasm, Doxorubicin, Traffic barrier, Cancer, Triple-negative breast cancer, Proteomics, AACR, Glioblastoma, Pancreatic cancer, Phenotype, PARP, Cisplatin, Immunogenic cell death, Large intestine, TNBC, Animal, PDGFR, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
  • Presentations from Novocure-sponsored and partner programs include:
    Tumor Treating Fields (TTFields) targeted self assembling nanoparticles for pancreatic cancer treatment: In vitro and in vivo assessment.
  • Tumor Treating Fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model.
  • Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib.

Regener-Eyes CEO C. Randall Harrell MD Recognized Among World's Top 2% of ALL Scientists by Stanford University and Elsevier

Retrieved on: 
Friday, October 20, 2023
Regenerative medicine, Memorial Hermann–Texas Medical Center, Stanford University, Ophthalmology, Harrell, MD, Texas Medical Center, Exosome, Medicine, Emory University, Dry, Eye, B cell, Medical device, Elsevier, Pericyte

TAMPA, Fla., Oct. 20, 2023 /PRNewswire/ -- Regener-Eyes®, led C. Randall Harrell, MD, the CEO and Chief Scientist, is proud to announce his inclusion in the top 2% of all scientists worldwide, as recognized by Stanford University and Elsevier.

Key Points: 
  • TAMPA, Fla., Oct. 20, 2023 /PRNewswire/ -- Regener-Eyes®, led C. Randall Harrell, MD, the CEO and Chief Scientist, is proud to announce his inclusion in the top 2% of all scientists worldwide, as recognized by Stanford University and Elsevier.
  • This prestigious acknowledgment, presented in a global database featuring elite scientists, is a testament to a lifetime of dedication and excellence.
  • Dr. C. Randall Harrell's illustrious career commenced at Emory University, where he contributed to the Department of Tumor Biology and Clinical Immunology.
  • Dr. Harrell says," This remarkable achievement reflects the collective success of our team, and I extend my heartfelt congratulations to all involved."

FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit

Retrieved on: 
Thursday, June 1, 2023
Astrocyte, Drug development, Central nervous system, Medium (website), IPSC, Pericyte, Stroke, 3D, Blood–brain barrier, DSM-IV codes, Pharmacokinetics, Hope, Physiology, Traffic barrier, Brain, Research, Cell, CNS, Neuroscience, Dementia, Animal, ICEL Psalter, Permeability, Patient, Drug discovery, Microglia, Neurological disorder, Migraine, WHO, IPS, Meningitis, World Health Organization, Medical imaging

The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.

Key Points: 
  • The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.
  • The iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready to use, human iPSC-derived cell model that has barrier integrity and functionality consistent with in vivo physiological properties.
  • The iCell Blood-Brain Barrier Isogenic Kit is commercially available and will begin shipping by the end of June 2023.
  • To learn more about FUJIFILM Cellular Dynamics’ blood-brain barrier cellular model, you can visit https://www.fujifilmcdi.com/icell-blood-brain-barrier-kit-coming-soon/ .

Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2023 ADDF-Harrington Scholar Award

Retrieved on: 
Monday, April 3, 2023
RFP, Neurovascular bundle, Drug development, Request, Pericyte, Alzheimer's disease, Request for proposal, University, Hypoxia (medical), University Hospitals Cleveland Medical Center, Dementia, Research, Brain, Astrocyte, Alzheimer's Drug Discovery Foundation, United Kingdom, Pharmaceutical industry

CLEVELAND, April 3, 2023 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.

Key Points: 
  • CLEVELAND, April 3, 2023 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award .
  • The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.
  • Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are strongly encouraged to apply.
  • This award provides a combination of financial support and expert drug development guidance to provide optimal support for moving research beyond the bench to the bedside.

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

Retrieved on: 
Wednesday, September 7, 2022
Professional Services, Health, Neurology, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, HIV disease progression rates, Locus coeruleus, Safety, Heart rate, Neuron, LC, Therapy, Arm, Cognition, Doctor of Philosophy, Brain, Microglia, Memory, Even and odd functions, Pericyte, Union, Cell, Neurodegeneration, MCI, Astrocyte, Patient, Arousal, Perfusion, Biomarker, Mutation, Pharmaceutical industry

The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.

Key Points: 
  • The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.
  • The multi-center trial , which is expected to enroll approximately 40 patients, is being conducted in the United States and New Zealand.
  • CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinsons disease, Alzheimers disease and other related orphan conditions.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (PDRBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.

Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Invite Proposals for 2022 ADDF-Harrington Scholar Award

Retrieved on: 
Friday, June 17, 2022
Fillit, Doctor of Philosophy, Investor, University Hospitals Cleveland Medical Center, Drug development, Case Western Reserve University, Science, Hypoxia (medical), Pericyte, Brain, Entrepreneurship, RFP, Research, Risk, Alzheimer's Drug Discovery Foundation, Dementia, Astrocyte, Request for proposal, Request, University, Partnership, Patient, United Kingdom, Center, Pharmaceutical industry, Alzheimer's disease, MD, Neuropsychiatry

CLEVELAND, June 17, 2022 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2022 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias. 

Key Points: 
  • CLEVELAND, June 17, 2022 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2022 ADDF-Harrington Scholar Award .
  • TheADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias.
  • Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are also encouraged to apply.
  • "The ADDF-Harrington Scholar Award demonstrates our commitment to developing diverse new classes of medicines that are not otherwise traditionally pursued in the field."

InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics

Retrieved on: 
Monday, January 24, 2022
Stem Cells, Biotechnology, Physical Therapy, FDA, Health, Pharmaceutical, Research, Hospitals, Surgery, Science, Clinical Trials, Stem cell, Patient, Technology, Orthopedic surgery, Journal, B cell, RT, Journal of Orthopaedic Surgery and Research, M.A, Adipose tissue, Fibroblast, Pericyte, New Orleans, Lists of diseases, Regeneration, Department, Review, Microdeletion syndrome, Ludwig Maximilian University of Munich, Lundeen, Tulane University, FDA, Cell, Physician, Endothelium, Furia, Pharmaceutical industry, Fine chemical, Medical device, Research, InGeneron, Political movement, the Transpose® RT System and Current Clinical Trials, InGeneron, THE TRANSPOSE® RT SYSTEM AND CURRENT CLINICAL TRIALS, INGENERON

InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called stem cell therapy, to treat orthopedic indications.

Key Points: 
  • InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called stem cell therapy, to treat orthopedic indications.
  • The publication provides an approachable overview of stem cell biology and clarifies common misconceptions about adipose-derived regenerative cells (ADRCs) including vascular-associated pluripotent stem cells (vaPS cells).
  • Summarizing 20 years of both basic and clinical research, the review aims to provide a straightforward look at the current state of orthopedic regenerative cell therapies and clarifies the role of different regenerative cells, such as vaPS cells, in tissue regeneration.
  • InGenerons Transpose RT cell therapy platform consists of a processing unit, a set of disposables, and Matrase, a proprietary enzyme mixture.

Emulate Brain-Chip to Study the Effects of Microgravity on Human Brain Physiology at the International Space Station

Retrieved on: 
Tuesday, December 21, 2021
Other Defense, White House, Federal Government, Other Health, Pharmaceutical, Medical Devices, Defense, Public Policy, Government, Genetics, Air, Transport, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Pericyte, Twitter, National Center for Advancing Translational Sciences, Founders Fund, ISS National Lab, Â, Environment, National Center for Research Resources, Health, National, LinkedIn, Astrocyte, Microglia, ISS, USB, Research, Disease, Scientist, Traffic barrier, Thumb, NASA, BBB, Harvard University, NCATS, Biology, Wyss Institute for Biologically Inspired Engineering, Immune system, Wyss Institute, NIH, Permeability, Perfusion, Engineering, Medical imaging, Emulate

The ISS provides an environment where researchers can study human health in microgravity, allowing them to isolate the effects of gravity from other factors that can impact brain cell function.

Key Points: 
  • The ISS provides an environment where researchers can study human health in microgravity, allowing them to isolate the effects of gravity from other factors that can impact brain cell function.
  • The Emulate Brain-Chip is the most comprehensive in vitro model of the human neurovascular unit, including the blood-brain barrier (BBB), for preclinical research.
  • It contains five cell types in a dynamic and tunable microenvironment, resulting in in vivo-like gene expression and phenotypic response.
  • The vascular channel is lined with brain microvascular endothelial cells, while the brain channel contains cortical neurons, astrocytes, pericytes, and microglia.